Dr Reddy's Laboratories Ltd(us:RDY)
13.24
+0.08%
Updated on 2025-04-03
Open:13.22
Close:13.24
High:13.37
Low:13.15
Prev Close:13.23
Volume:2.02M
Turnover:26.85M
Turnover Ratio:0.24%
Shares:834.45M
MarketCap:11.05B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 7 | 15668 | 0.01% | 1 | 3 | 3 |
| 2024-03-31 | 242 | 23521179 | 14.10% | 27 | 91 | 90 |
| 2023-12-31 | 240 | 23451492 | 14.06% | 36 | 79 | 88 |
| 2023-09-30 | 218 | 22568214 | 13.53% | 31 | 87 | 69 |
| 2023-06-30 | 210 | 20693770 | 12.42% | 23 | 80 | 74 |
| 2023-03-31 | 200 | 19196698 | 11.53% | 41 | 69 | 59 |
| 2022-12-31 | 178 | 16411213 | 9.86% | 32 | 60 | 57 |
| 2022-09-30 | 162 | 16326984 | 9.81% | 20 | 61 | 54 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Blackrock Inc. | 2178458 | 1.31% | -822962 | -27.42% |
| 2024-03-31 | Royal Bank Of Canada | 2164345 | 1.30% | -55462 | -2.50% |
| 2024-03-31 | Robeco Institutional Asset Management B.V. | 1974720 | 1.18% | 249340 | 14.45% |
| 2024-03-31 | Renaissance Technologies Llc | 1929889 | 1.16% | 69094 | 3.71% |
| 2024-03-31 | Goldman Sachs Group Inc | 1559128 | 0.93% | -278035 | -15.13% |
| 2024-03-31 | Aikya Investment Management Ltd | 1239935 | 0.74% | 143362 | 13.07% |
| 2024-03-31 | Vanguard Group Inc | 1019011 | 0.61% | -19247 | -1.85% |
| 2024-03-31 | Bank Of America Corp /De/ | 891650 | 0.53% | 329097 | 58.50% |
| 2024-03-31 | Dimensional Fund Advisors Lp | 889488 | 0.53% | 60178 | 7.26% |
| 2024-03-31 | Morgan Stanley | 876889 | 0.53% | 58337 | 7.13% |
About
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Address:Door No. 8-2-337,Road No. 3,Banjara Hills
Website:http://www.drreddys.com
Market Movers